Compare ARTNA & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARTNA | LYEL |
|---|---|---|
| Founded | 1905 | 2018 |
| Country | United States | United States |
| Employees | 274 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.4M | 320.1M |
| IPO Year | N/A | 2021 |
| Metric | ARTNA | LYEL |
|---|---|---|
| Price | $33.37 | $12.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.60 |
| AVG Volume (30 Days) | 26.0K | ★ 136.7K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $3.54 | $8,712.13 |
| P/E Ratio | $15.23 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.50 | $8.63 |
| 52 Week High | $34.90 | $45.00 |
| Indicator | ARTNA | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 62.71 | 33.07 |
| Support Level | $31.86 | N/A |
| Resistance Level | $33.79 | $14.14 |
| Average True Range (ATR) | 0.68 | 1.01 |
| MACD | 0.07 | 0.15 |
| Stochastic Oscillator | 97.06 | 1.21 |
Artesian Resources Corp operates as a holding company based in the United States. Through its subsidiaries, it offers water, wastewater, and other services in Delaware, Maryland, and Pennsylvania. The Group distributes and sells water, including water for public and private fire protection, to residential, commercial, industrial, municipal, and utility customers. Additionally, it is involved in contract water and wastewater operations; offers wastewater services, and water, sewer, and internal Service Line Protection Plans. The Group operates its businesses mainly through one reportable segment, the Regulated Utility segment.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.